Rybelsus (Semaglutid)

Rybelsus UK
Rybelsus UK is a GLP-1 drug prescribed to treat type 2 diabetes. It contains the same active ingredient (semaglutide) as the popular, brand-name weight loss drugs Wegovy and Ozempic. Rybelsus® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes. It should be used with an appropriate diet and physical exercise. Novo Nordisk, the pharmaceutical company behind Rybelsus drug, also manufactures Ozempic and Wegovy. These drugs share the same active ingredient as Rybelsus, a compound called semaglutide.
It is not known if Rybelsus® can be used in people who have had pancreatitis, is not for use in people with type 1 diabetes, not known if it is safe and effective for use in children under 18 years of age Semaglutide medication belongs to the category of drugs known as glucagon-like peptide-1 receptor agonists. GLP-1 receptor agonists mimic the action of GLP-1, a hormone naturally produced in the intestines in response to food intake. When you eat, your intestines release GLP-1, signaling the pancreas to release insulin. Insulin helps the body absorb glucose (sugar) from the blood into cells for energy.

The starting dose for Semaglutide is 3 mg once daily. After one month, the dose should be increased to 7 mg once daily. If needed, the dose can be further increased up to a maximum of 14 mg once daily. Type 2 diabetes is a disease in which the body does not make enough insulin to control the level of glucose in the blood or when the body cannot use insulin effectively. The result is a high level of glucose in the blood. The active substance in Rybelsus, semaglutide, is a ‘GLP-1 receptor agonist’. It acts in the same way as GLP-1